Agenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Agenus Inc. (NASDAQ:AGEN) have been assigned an average rating of “Hold” from the five research firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating on the company. The average 1-year price target among analysts that have covered the stock in the last year is $14.50.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Agenus in a research note on Monday, December 29th.

Agenus Price Performance

Agenus stock opened at $3.27 on Monday. The business has a 50 day simple moving average of $3.27 and a 200-day simple moving average of $3.87. Agenus has a 12 month low of $1.38 and a 12 month high of $7.34. The stock has a market capitalization of $111.25 million, a PE ratio of -1.53 and a beta of 1.56.

Institutional Investors Weigh In On Agenus

A number of institutional investors have recently added to or reduced their stakes in AGEN. Virtu Financial LLC purchased a new position in Agenus during the 4th quarter valued at about $108,000. EP Wealth Advisors LLC acquired a new stake in shares of Agenus in the fourth quarter valued at approximately $31,000. Quadrature Capital Ltd purchased a new position in shares of Agenus during the 4th quarter worth approximately $54,000. Man Group plc acquired a new position in shares of Agenus during the 4th quarter worth approximately $359,000. Finally, 683 Capital Management LLC purchased a new stake in Agenus in the 4th quarter valued at approximately $359,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.